ViennaLab StripAssay - Model EGFR XL -Gene Therapy

NSCLC comprises approximately 85% of all lung cancers. Tumor specimens from patients should be tested for the presence of EGFR mutations prior to TKI treatment. The EGFR XL StripAssay® and EGFR T790M RealFast™ Assay are designed to assist clinicians in the stratification of patients considered for TKI therapy.